MedTrace Logo

Biomarker Development in LGMD2i

NCT04202627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2023-03-29

No results posted yet for this study

Summary

The overall goal of this natural history study is to define the key LGMD2i phenotypes as measured by standard clinical outcome assessments (COAs), and to validate a muscle biomarker for LGMD2i to support therapeutic development.

Conditions

  • Muscular Dystrophies
  • Limb Girdle Muscular Dystrophy

Sponsors & Collaborators

  • Virginia Commonwealth University

    collaborator OTHER

  • ML Bio Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicholas E Johnson, MD · Virginia Commonwealth University

Eligibility

Min Age
10 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2022-10-10
Completion
2022-10-10

Countries

  • United States
  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202627 on ClinicalTrials.gov